biodel inc (BIOD) Key Developments
Biodel Inc. Presents at 2nd Annual ROTH Healthcare Day, Jun-24-2015
Jun 9 15
Biodel Inc. Presents at 2nd Annual ROTH Healthcare Day, Jun-24-2015 . Venue: The Dorchester, 53 Park Lane, Mayfair, London, W1K 1QA, UK, United Kingdom. Speakers: Errol B. De Souza, Chief Executive Officer, President and Director.
Biodel Inc. Announces the Initiation of a Phase 2b Clinical Trial of BIOD-531
May 21 15
Biodel Inc. announced the initiation of a Phase 2b clinical trial of BIOD-531, the company's concentrated, proprietary, recombinant human insulin (RHI) based ultra-rapid-acting prandial/basal combination insulin candidate. The Phase 2b trial, Study 3-250, is a randomized, open-label, parallel group study in patients with insulin-treated type 2 diabetes. Approximately 130 patients are targeted for enrollment at 25 U.S. investigative centers. Patients will be randomized to receive either BIOD-531 or Humalog(R) Mix 75/25 dosed twice daily. Patients will be treated for 18 weeks, the first six weeks of which will focus on active dose titration. The primary analysis will evaluate change from baseline in HbA1c, while secondary endpoints will compare postprandial glucose excursions, hypoglycemic event rates and weight changes. Top line results are expected in mid-2016.
Biodel Inc. Appoints Arlene M. Morris to its Board of Directors
May 18 15
Biodel Inc. announced the appointment of Ms. Arlene M. Morris to its board of directors. Ms. Morris was recently the President and CEO of Syndax. Previously, she was the president, chief executive officer and member of the board of directors of Affymax Inc. Prior to Affymax, Ms. Morris was the president and CEO of Clearview Projects.
Biodel Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2015
May 6 15
Biodel Inc. reported unaudited consolidated earnings results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported loss before tax provision of $4,355,000 against $6,194,000 a year ago. Net loss was $4,356,000 or $0.18 per basic and diluted share against $6,198,000 or $0.29 per basic and diluted share a year ago.
For the six months, the company reported loss before tax provision of $9,040,000 against $8,631,000 a year ago. Net loss was $9,043,000 or $0.40 per basic and diluted share against $8,640,000 or $0.41 per basic and diluted share a year ago.
Biodel Inc. to Report Q2, 2015 Results on May 06, 2015
May 1 15
Biodel Inc. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on May 06, 2015